DENTSPLY SIRONA Swings to Q2 Loss Amidst Challenging Market

Ticker: XRAY · Form: 10-Q · Filed: 2025-08-07T00:00:00.000Z

Sentiment: bearish

Topics: Dental Equipment, Medical Devices, Earnings Miss, Net Loss, Shareholder Equity, Q2 2025, Profitability Concerns

Related Tickers: XRAY

TL;DR

**XRAY's Q2 loss is a major red flag; dump shares before the market bites back.**

AI Summary

DENTSPLY SIRONA Inc. reported a net loss of $10.9 million for the second quarter of 2025, a significant decline from a net income of $20.1 million in the prior-year quarter. For the six months ended June 30, 2025, the company posted a net loss of $1.9 million, compared to a net income of $30.1 million for the same period in 2024. While specific revenue figures were not provided in the excerpt, the shift from profit to loss indicates potential challenges in sales or increased operational costs. The company's accumulated other comprehensive income decreased from a negative $1.0 million at December 31, 2024, to a negative $1.2 million at June 30, 2025, reflecting adverse movements in other comprehensive income. Total equity attributable to DENTSPLY SIRONA Inc. shareholders decreased from $6.901 billion at December 31, 2024, to $6.888 billion at June 30, 2025, indicating a slight erosion of shareholder value. The company's strategic outlook likely involves addressing these profitability issues and managing its capital structure effectively.

Why It Matters

This swing to a net loss for DENTSPLY SIRONA Inc. is a red flag for investors, signaling potential operational inefficiencies or weakening demand in the dental equipment and supplies market. For employees, this could indicate future cost-cutting measures or hiring freezes. Customers might see impacts on product development or service levels if the company tightens its belt. In a competitive landscape, this performance could allow rivals to gain market share, putting pressure on DENTSPLY SIRONA's long-term position and potentially affecting the broader dental industry's investment sentiment.

Risk Assessment

Risk Level: high — The company reported a net loss of $10.9 million in Q2 2025, a substantial drop from a $20.1 million net income in Q2 2024. This significant swing to unprofitability, coupled with a decrease in total equity attributable to shareholders from $6.901 billion to $6.888 billion, indicates deteriorating financial health and heightened investment risk.

Analyst Insight

Investors should consider divesting XRAY shares or shorting the stock given the significant swing to a net loss and declining shareholder equity. Monitor upcoming earnings calls for management's plan to address profitability and market share challenges.

Key Numbers

-$10.9M — Net Income (Q2 2025) (Represents a swing from a $20.1M net income in Q2 2024, indicating significant profitability challenges.)
-$1.9M — Net Income (YTD June 2025) (Compared to a $30.1M net income for the same period in 2024, highlighting a year-to-date loss.)
$6.888B — Total Equity (June 30, 2025) (Decreased from $6.901B at December 31, 2024, showing a reduction in shareholder value.)
-$1.2M — Accumulated Other Comprehensive Income (June 30, 2025) (Worsened from -$1.0M at December 31, 2024, reflecting adverse non-owner changes in equity.)

Key Players & Entities

DENTSPLY SIRONA Inc. (company) — filer of the 10-Q
$10.9 million (dollar_amount) — net loss for Q2 2025
$20.1 million (dollar_amount) — net income for Q2 2024
$1.9 million (dollar_amount) — net loss for six months ended June 30, 2025
$30.1 million (dollar_amount) — net income for six months ended June 30, 2024
$1.0 million (dollar_amount) — negative accumulated other comprehensive income at Dec 31, 2024
$1.2 million (dollar_amount) — negative accumulated other comprehensive income at June 30, 2025
$6.901 billion (dollar_amount) — total equity attributable to shareholders at Dec 31, 2024
$6.888 billion (dollar_amount) — total equity attributable to shareholders at June 30, 2025
SEC (regulator) — recipient of the 10-Q filing

FAQ

What was DENTSPLY SIRONA's net income for Q2 2025?

DENTSPLY SIRONA Inc. reported a net loss of $10.9 million for the second quarter of 2025, a significant decrease from a net income of $20.1 million in the same period of 2024.

How did DENTSPLY SIRONA's year-to-date net income compare in 2025 versus 2024?

For the six months ended June 30, 2025, DENTSPLY SIRONA Inc. posted a net loss of $1.9 million, which contrasts sharply with a net income of $30.1 million for the corresponding period in 2024.

What happened to DENTSPLY SIRONA's total equity attributable to shareholders?

Total equity attributable to DENTSPLY SIRONA Inc. shareholders decreased from $6.901 billion at December 31, 2024, to $6.888 billion at June 30, 2025, indicating a slight reduction in shareholder value.

What is the significance of the change in accumulated other comprehensive income for DENTSPLY SIRONA?

DENTSPLY SIRONA's accumulated other comprehensive income worsened from a negative $1.0 million at December 31, 2024, to a negative $1.2 million at June 30, 2025, reflecting adverse non-owner changes in equity, potentially from currency translation adjustments or unrealized gains/losses on investments.

What are the primary financial concerns for DENTSPLY SIRONA based on this 10-Q?

The primary financial concerns for DENTSPLY SIRONA Inc. are the significant swing from net income to a net loss in both the second quarter and year-to-date periods, and the slight erosion of total shareholder equity, indicating profitability and value creation challenges.

How might DENTSPLY SIRONA's Q2 2025 performance impact its competitive standing?

DENTSPLY SIRONA's Q2 2025 net loss could weaken its competitive standing in the dental equipment and supplies market, potentially allowing competitors to gain market share if the company struggles to invest in innovation or maintain pricing power.

What does the 10-Q suggest about DENTSPLY SIRONA's operational efficiency?

The shift from net income to a net loss for DENTSPLY SIRONA Inc. suggests potential issues with operational efficiency, either through declining sales volumes, increased cost of goods sold, or higher operating expenses, which are impacting overall profitability.

What should investors consider regarding DENTSPLY SIRONA's stock (XRAY) after this filing?

Investors should consider the significant financial deterioration, including the net loss and declining equity, as a high-risk signal for DENTSPLY SIRONA's stock (XRAY). Further investigation into the causes of the loss and management's mitigation strategies is warranted.

Are there any positive indicators for DENTSPLY SIRONA in this 10-Q?

Based solely on the provided excerpt, which highlights a swing to net losses and declining equity, there are no explicit positive financial indicators for DENTSPLY SIRONA Inc. in this 10-Q filing.

What is the overall risk assessment for DENTSPLY SIRONA based on the Q2 2025 10-Q?

The overall risk assessment for DENTSPLY SIRONA Inc. is high, primarily due to the substantial net loss of $10.9 million in Q2 2025 and the year-to-date net loss of $1.9 million, indicating significant financial underperformance and potential operational challenges.

Industry Context

DENTSPLY SIRONA operates in the dental equipment and supplies industry, a sector characterized by technological innovation and a focus on both professional and consumer dental health. The competitive landscape includes established players and emerging companies offering a range of products from consumables to advanced digital imaging and treatment solutions. Trends include the increasing adoption of digital dentistry, demand for minimally invasive procedures, and a growing emphasis on preventative care.

Regulatory Implications

As a medical device manufacturer, DENTSPLY SIRONA is subject to stringent regulations from bodies like the FDA in the United States and similar agencies globally. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Changes in healthcare policies or increased scrutiny on product safety and efficacy could impact market access and operational costs.

What Investors Should Do

[object Object]
[object Object]
[object Object]
[object Object]

Key Dates

2025-06-30: End of Second Quarter 2025 — Reporting period for the net loss of $10.9 million and a decrease in total equity.
2025-06-30: Accumulated Other Comprehensive Income as of June 30, 2025 — Reported at -$1.2 million, indicating a worsening trend from the prior period.
2025-06-30: Total Equity as of June 30, 2025 — Stood at $6.888 billion, a slight decrease from $6.901 billion at the end of 2024.
2025-04-01: Start of Second Quarter 2025 — Beginning of the period that resulted in a net loss.
2024-06-30: End of Second Quarter 2024 — Prior year period when the company reported a net income of $20.1 million.
2024-12-31: End of Fiscal Year 2024 — Reference point for the beginning balance of accumulated other comprehensive income (-$1.0 million) and total equity ($6.901 billion).

Glossary

Accumulated Other Comprehensive Income: Represents the cumulative amount of unrealized gains and losses that have not been recognized in net income. This includes items like foreign currency translation adjustments and unrealized gains/losses on certain investments. (A decrease in this figure, as seen from -$1.0 million to -$1.2 million, suggests adverse movements in these non-operating income/loss items, impacting the overall equity.)
Total Equity: The net worth of the company, calculated as total assets minus total liabilities. It represents the owners' stake in the company. (The decrease from $6.901 billion to $6.888 billion indicates a slight erosion of shareholder value during the period.)
Net Loss: Occurs when a company's expenses exceed its revenues over a specific period. (The company reported a net loss of $10.9 million in Q2 2025, a significant shift from the net income of $20.1 million in the prior-year quarter, highlighting profitability concerns.)

Year-Over-Year Comparison

The second quarter of 2025 shows a significant deterioration in profitability compared to the prior year, with a net loss of $10.9 million versus a net income of $20.1 million in Q2 2024. This swing from profit to loss, along with a year-to-date net loss of $1.9 million compared to a $30.1 million profit, indicates substantial challenges. Total equity has seen a slight decrease, and accumulated other comprehensive income has worsened, suggesting adverse financial movements beyond core operations.

From the Filing

0000818479-25-000155.txt : 20250807 0000818479-25-000155.hdr.sgml : 20250807 20250807091800 ACCESSION NUMBER: 0000818479-25-000155 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DENTSPLY SIRONA Inc. CENTRAL INDEX KEY: 0000818479 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 391434669 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-16211 FILM NUMBER: 251192027 BUSINESS ADDRESS: STREET 1: 13320 BALLANTYNE CORPORATE PLACE CITY: CHARLOTTE STATE: NC ZIP: 28277-3607 BUSINESS PHONE: 844-546-3722 MAIL ADDRESS: STREET 1: 13320 BALLANTYNE CORPORATE PLACE CITY: CHARLOTTE STATE: NC ZIP: 28277-3607 FORMER COMPANY: FORMER CONFORMED NAME: DENTSPLY INTERNATIONAL INC /DE/ DATE OF NAME CHANGE: 19930630 FORMER COMPANY: FORMER CONFORMED NAME: GENDEX CORP DATE OF NAME CHANGE: 19920703 10-Q 1 xray-20250630.htm 10-Q xray-20250630 0000818479 12/31 2025 Q2 FALSE http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent xbrli:shares iso4217:USD iso4217:USD xbrli:shares xray:segment xbrli:pure xray:business_unit xray:reporting_unit xray:year iso4217:EUR 0000818479 2025-01-01 2025-06-30 0000818479 2025-07-18 0000818479 2025-04-01 2025-06-30 0000818479 2024-04-01 2024-06-30 0000818479 2024-01-01 2024-06-30 0000818479 2025-06-30 0000818479 2024-12-31 0000818479 us-gaap:CommonStockMember 2024-12-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000818479 us-gaap:RetainedEarningsMember 2024-12-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000818479 us-gaap:TreasuryStockCommonMember 2024-12-31 0000818479 us-gaap:ParentMember 2024-12-31 0000818479 us-gaap:NoncontrollingInterestMember 2024-12-31 0000818479 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000818479 us-gaap:ParentMember 2025-01-01 2025-03-31 0000818479 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000818479 2025-01-01 2025-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000818479 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000818479 us-gaap:CommonStockMember 2025-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000818479 us-gaap:RetainedEarningsMember 2025-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000818479 us-gaap:TreasuryStockCommonMember 2025-03-31 0000818479 us-gaap:ParentMember 2025-03-31 0000818479 us-gaap:NoncontrollingInterestMember 2025-03-31 0000818479 2025-03-31 0000818479 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000818479 us-gaap:ParentMember 2025-04-01 2025-06-30 0000818479 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0000818479 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000818479 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000818479 us-gaap:CommonStockMember 2025-06-30 0000818479 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000818479 us-gaap:RetainedEarningsMember 2025-06-30 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000818479 us-gaap:TreasuryStockCommonMember 2025-06-30